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Homocysteine is increasingly recognized as a risk factor for 
coronary artery disease. An understanding of its metabolism and 
of the importance of vitamins B, and B,, and folate as well as 
enzyme levels in its regulation will aid the development of 
therapeutic strategies that, by low&tg circulating concentra- 
tions, may also lower risk. Possible mechanisms by which elevated 
homocysteine levels lead to the development and progression of 
The conventional risk factors for premature coronary artery 
disease include smoking, hyperlipidemia, hypertension, diabc- 
tes and a positive family history. However, many patiems have 
precocious atherosclerosis without having any of these stan- 
dard risk factors. Identification of other markers that increase 
the risk of coronary disease may improve our understanding 
of the pathophysiologic mechanisms of this disorder and allow 
the development of new preventive or therapeutic measures. 
An elevated plasma homocystcine level has recently received 
greater attention as an important risk factor for vascular 
disease, including coronary atherosclerosis. This review dis- 
cusses the biochemistry of homocysteine sod the related 
metabolic importance of folate, vitamin 6, (pyridoxine) and 
B,, (cobalamin) as well as a number of essential enzymes. The 
major factors that influence homocysteine concentration are 
gene!ic: nutritional and pathologic. The natural history, char- 
acteristic pathology and pathophysiology of homocystinuria, a 
syndrome of abnormal homocysteine metabolism, are exam- 
ined as the paradigm of thromboembolic disease and high 
circuiating homocystcine concentrations. Additionally. there is 
a large body of experimental and clinical evidence for high 
plasma homocvsteinc to bc a risk factor for vascular disease, 
including coronary atherosclerosis. Most important, recent 
research has dcmdnsrrated interventions capable of reducing 
plasma homocysteine, and further research will be needed to 
determine their impact on mortality and morbidity associated 
with cardiovascular disease. 
From the Dcpartmcnts c>f r.lrcfiol3gy. &!I Siolc~ and Clinical Patholog. 
The Research Iwtitute. The Clcwknd Clinic Foundation and Ohio State 
Uniwsity, Clwelxtd: Ohio. 
Mmuwipt rexived July 6. 1995; revised manuscript received Octohx 6. 
19Y5, wepted October Il. 1995. 
Addrss for cqesmndence: Dr. Kiliian Robinson. Department of Cardiol- 
og, Cleveland Clinic Foundation, 9500 Euclid Avenue. Cleveland. Ohio 44195. 
~Blo96 hy the Amcricsn C4ep of Cardiolog) 
Published hy Elsevier SciL-rice Inc. 
- 
vascular disease include effects on platelets, c?otting factors and 
endothelium. This review prest-iits ihe cLin;cal and basic scientific 
evidence supporting the risk and mechanisms of vascular disease 
associated wjth elevated homocysteine concentrations as well as 
the results of preliminary therapeutic trials. 
(J Am Coil CurEioi 1996:27:517-27) 
Homocysteine Metabolism 
Homocys:eine is an intcrmediatc Cormed during the metab- 
olism of methioninc. an essential suWur-containing amino acid 
supplied from dietary proteins. The recommended dietary 
allowance for methionine in U.S. adults is 0.9 giday (l), and the 
estimated adult intake in this country is -2 @day. The first step 
in the metabolism of methionine (Fig. I) is the formation of 
the intermediate S-adenosylmethioninc, which is an importan: 
methyl donor in manv transmethylation reactions (2). S- 
Adcnosylmethionine is demethylated to form S-adenosyl- 
homocystcine. whrch is then hydrolyzed to adenosine and 
homocysteinc. Homocysteine then either enters the transsul- 
furation pathway or the rcmethylatron cycle. Approximaiely 
50% enters the transsulfuration pathway, where it is irrevers- 
ibly combined with serine by the E&-dependent enzyme cysta- 
thioninc zeta-synthase to form cystathionine. This is then 
metabolized to cysteine and alpha-ketobutyrate by gamma- 
cystathionase, another B,-dependent enzyme. In situations of 
excess methionine, the transsulfuration pathway is favored by 
up-regulation of cystathionine beta-synthase and down- 
regulation of the remethylation pathway (3). The cysteine that 
is formed from homocysteine is ultimately converted to the 
sulfate and is excreted in the urine. 
In the remethylation pathway, homocysteine is recycled to 
methionine by two different reactions. The first requires the 
presence of S-mcthyltetrahydrofolate-homocysteine methyl- 
transfcrase (methionine synthase). Methylcobalamin and 
methyltetrahydrofolate serve as cofactor and cosubstrate for 
this enzyme. The remethylation pathway is favored during 
relative methionine deficiency. and this recycling and con- 
servation of homocysteine ensures adequate methionine main- 
tenance (2). .4 second pathway exists for homocysteine re- 
methylation catalyzed by the enzyme betaine-homocystcine 
methyltransferase (2). 
Homocysieine is thus an important reflection of the status 
of methionine metabolism, and its metabolic fate can be 
t 
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Urine 
Figure 1. Methiuninl: cycle: mct&lic parhwnys of hnmocyslcin- 
mciabolism. DMG = dimcthylglycinc: MTIIF = mcthylenelctrahy- 
droiiilatu: NADP’ y: nicolinan;idc adenint diniiclsotidr phclsph;ite 
(o:Gdizcd form); NADPtI = nicorinamidc atlcninc dinuclcotidc phos- 
ph,lle (reduced form). 
%?Iucnced by alterations in the concentrations of folatc, B,,, 
pcbaiamin or activities of the various enzymes that participate 
in the transsulfuration or remcthylation pathways. Normally, 
the intracellular concentration of homocysteine is kept within 
narrow bounds (4), anti any increase in production (5) 01 
reduction in metabolism (6) is mci by export from cells. 
Convcnciy, if the formation of homocysteinc is reduced, 
export from cells decreases (7). The concentration of homo- 
cystcine in blood is therefore an important reflection of its 
intracellular concentration and of the integrity of the various 
pathways responsible for its metabolism. 
Circulating forms of homocgsteine and determination. Ap- 
proximately 80% of homocysteine in blood is protein bound by 
disulfide linkage (8). The remaining unbound homocysteine 
combines by oxidation either with itself to form the dimet 
homocysteine or with cystcine to form the mixed disulfidc 
cysteine-homocysteine. Only a small amount circulates as free 
homocysteine (8). When blood is drawn, fret hornocystcinc 
becomes protein bound, even when samples are frozen imme- 
diately (9j. In such samples, therefore, free homocysteine may 
be variable, hut total llomocysteine remains constant. How- 
ever, total homocysteinc may increase if whole blood is stored 
at room temperature; this may rcllcct the export of homocys- 
teine from red blood cells (10). 
Many early clinical studies of homocystcinc used plasma 
mixed disulfidc (I i-14). homocystcinc (17.14) or protein-bound 
homcicystcinc (l-5) as indicators of homocystcinc status. In 
1985. Rcfsum et al. (9) developed an assay for the dctcrmina- 
tion of total homocystcine. including both protein-bound and 
free fracii0n.s; another assay for total homocystcine was devcl- 
opcd at the Clcvcland Clinic Foundation (IO). Fasting samples 
have been widely used for the measurement of plasma homo- 
cystcinc. Malinow et al. (17) rcporied similar values for fasting 
and postprandial sampleh, although small ditfercnccs have 
been reported by others (IX). However, for standard reference 
purposes, total fasting plasma homocystcine is recommended. 
Samples of blood should hc placed on ice immediately on 
drawing and the cellular components removed within 2 to 3 h. 
Values in a normal popuiation may vary slightly bctwecn 
laboratories but usually lie in the range: of 2 to IS pmoliliter in 
the fasting state (Ih,lS). A level greater than this is often 
refcrrcd to as I~~~~crhorlroc)!rrci,le!llin. 
Methionine loading test. In some subjects with impaired 
homocysteinc mctabotism, fasting concentrations may bc nor- 
mal. A methionine loading test may be used to expose this 
latent abnormality (4). Similar in principle to the glucose 
tolcrancc test, loading is performed by the administration of an 
oral dose of methionine, 0.10 g/kg body weight. Plasma homo- 
cystcinc levels increase and may he measured 2,4,h or 8 h later 
(12,13) (Fig. 2). There is some variability in the time at which 
peak values are seen: free homocystcine levels may peak at 2 to 
3 h, whereas protein bound levels may peak later at 4 to 6 h (4). 
Recent studies of homocysteine in disease states have utilized 
fasting total homocysteine concentrations (19-22), with con- 
Fiiure t. Melhionine loading curve: c&t of mcthioninc loading on 
plasma homncystcinc concentrations. Reprilited \rilh permission from 
Wand ct al. (4). 
elusions similar lo lhosc of cat-licr siudics utilizing the IllCilli- 
onine loac!ing test (1 I-13). (Jivcn ihc cost and time rquired to 
perform the methionine loading study, 3 single fasting sample 
may he the most cost-cffectlve test. 
crcatir;inc ~.~alues (41) or the grMer muscle mass of men than 
Woi1lEn (.x3). 
Renal function. There is a positive correlahn bct\vct’n 
fasling plasma liomwyskA:is arid serum creatininc (22,.:k), 
i!iougli tlic mechanism is u~lesr. Both rennvnscular arterio- 
scicrosis and prcrenal f;l::tors may he important (22). In 
chronic renal failure. plasma hnmocystrine levels may be IW 
to four times normal (42,43). These conccntrstions dccre‘ase 
at& dialysis (43). Increases in homocysteinc in renal failure 
may result from impaired metabolism rather than excretion 
(43). 
Nutrition. Vircrrr~ir~ R,,ifnhr. I-Ioniocysteine levels can br 
markedly clevatcd in dcticiencics of the csscntisl cofactor 
\:it,tmin I3,, (44) or of the cosubst:alc folate (45,4h). Indecti. 
plxna homocysteinc levels may hc cicvated cvcn when sc’rum 
B,, and Mate levels arc in the low normal range (37.43.47). 
Negative correlations hrtwcen serum iolate and I?,? and 
homocystcinc have been seen in studies of normal subjrcts 
(16.37.4S.49). 
Factors Influencing Homocysteine 
Metabokm and Causes 
of Myperhomocysteinemia 
Vifnrtzin B,. There arc conflicting result\ concerning the 
clTccts of vitamin I3,, deficiency on homocystcine in humans 
(4X.%). although negative correlations similar to those sfen 
with B:, and folate have been observed in normal subjects 
Plasma homocystcinc concentration:; are regulated by a num- 
ber of enzymes, essenti:J cofactors and the availability of the 
important cosuhstratc methyltetrahydrofolate. Prcdictahly. rhc 
causes of hyperhomocy:,tcincmia are multifactoria! (Table I ). 
Genetics. Homozygotcs for classical homocysGnuria have 
low or undetcctablc activity of cystathioninc betasynthasc and 
a characteristic cxccssivcly clcvntcd plasma homocystcinc. 
Conversely, bccausc th: gene for cystathioninc beta-synthusc is 
located on chromosome 21 (4). increased acfivity of cystathi- 
onine beta-synthase might be expected in trisomy 21 Down 
syndrome. Decreased total plasma homocysteine was found in 
eight pediatric paticn;s with Down syndrome (4). A Gong 
genetic infucnce on plasma homocystcine concentration has 
also been seen in sttldies of normal subjects (23) and in 
patients with vascular disease (20,24,2S). Inherited remethyla- 
tion cycle abnormalities have been described, including de- 
rangemcnts of methionine synthase caused by disorders of 
cobalamin metabolism (4,27-29). A number of disorders of 
methylenctetrahydrofolatc rcductasc have also heen described 
(4.30-36). In some of these, the precise genetic abnormalities 
have been identified (32-M). In all these situations, elevated 
homocysteine concentrations may bc seen. 
Age. Plasma homocysteine levels increase with age (4,lS) 
for reasons that are obscure. Decreases in cofactor levels 
(37,38) or coexisting renal impairment often seen in older 
patients ~rtay he responsible. and age-dcpendcnt reductions in 
cystathionine beta-synthase activity may also play a part (39). 
Gender. In general, men have higher plasma ievels than 
women (IS,I6). Levels increase in both genders with age (15). 
After menopa;lse, fasting homocysteine concentrations may 
increase (15.40) or remain unchanged (X). Although gender 
differences may be explained by the effect of sex hormones 
on homoqsteine metabolism, they may be related to higher 
(37). 
Table 1. Factors Intlucncing tlornocgstcinc I..~vcls 
A. Homo;yskine increases with age 
B. Homocystrinc levels: men > age--matched women 
C. Pwmenapausal women: homocyacine levcl~ ircrcast 
111. Rcnal function: homocysicmc increnscr with incrcancd CR Nininc 
IV. Nulririon 
A. Vitamin B, dcfickncy 
R. Vlramin B,? deficient 
C’. I=ohe dcfirwKy 
V. !)iseasc sla1es 
A. Severe psoriasis. astwated with incwawd homoc@zinc lea& 
(possibly related :o her f&k levels) 
U. Cancer. acuie Iymphoblaslic le\iliemia. elevated Icv~ls 
C. Chronic renal failure. incrcascd hnmncystcinc. lnwcrcd with dialysis 
V!. Medications 
A. Increase homocystcise 
1. Methotrenale. dzpleles .i-meihyltctrah)jrofolatc 
2. Azarihine, vitamin R,, amagonist 
3. Nitrous oxide. inactivates vitamin B,, 
4. Phqtoin. inrerfcrrs with foiate mclaholism 
5. Carhamatcpine. imerfcres with folalc mclaholiw~ 
6. filmgcn-c,Maining orai contmceptivcs, induce vitamin 11, 
dclicicnq 
(~mcr~. h4:irktdlp elcvat~d homoc~stcin~ /C\T!S Iwc IWXI 
seen in actitc lymphob!asfic lC!lkCi?ii~l am! dccrwsc niwr 
trealrl;::nt witi1 l?;ioro\;ic drugs (5 1 i. M~!i/C~,lfc‘!); ClC\YltCc! hi?- 
IlliXJ~SlL’iliC c:llKclltr4fiilfiS tl;b~c BlS0 t?Ccrl Sc’cll in palic:ntl, wiih 
v;rritws carcinomas. inoludmp hrwsi. waris ani pancrmtir. 
who had highly elevated tumor markers. Serial samples from 
many of these patients demonstrated parallrl changes in 
homocysteine concentration and tumor marker ievc!; (52). 
Methionine metabolism may he altered in malignan: cclis: 
MoiI transformed cel!s. in con:rasl to nontransformed cc!!% 
arc methioninc tlcpcndent in culturc and arc u~~~hlc to uti!iic 
homocystcinc in mcdlri (53). Pliihll;a Icvcls rtl;iy 11~: rchcd to 
the large hurdcn of protifcrating cells unal~lc !n utilize rondo- 
gcnous homncysteinc. 
Drugs. Pliismii hcimocystcine Icvcis may ;li~o he inf?ucnccd 
by t~hnrm;lcolo~ic agents. including mcIho!rcxatc, nilrous ox- 
idc, phenytoin. ca;bamazcpinc, azarihinc. cstlogcn-cont:liiiing 
orat contraccptivrs and penicillamine (1.53). Methorrcxa~c 
depletes 5-,ilethyltctrahydrc,folate. the cosubstratc for methi- 
onine synrhase, and inducts a transient incrcasc in plasma 
homocysteinc (4.55). Nitrous oxide inactivates vitamin B,,- 
depcndsnt methianine synthase and is known to elevate 
plasma h(:mocysteine (4). Anticonvutsal~ts, such as phenytoin 
and carbamazepinc, which interfere with folatc meGolism, 
may also increase homocystcinc concentrations (?,53). 
Azarihine. initially tiscd for refractmy cases of psoriasis. is 
;I \ ilarnin B,, antago& and iuhihits cystathionine beta- 
synthasc, raising homocysteine levt:ts. In 1976, azaritiinc was 
prohihitcd by the Food and Drug Administration hecsusc it 
was associated with increased risk of thromt~oemhotism (4). 
The use of diuretic drugs (54) ~1 the lipid-lowering agents 
cotestipol and niacin in combination (55) have hren associated 
with ctcvated homocysteine levels. 
laholism of sulfur-containing amino acids, including homocys- 
teinc (53). Although women taking oral contraceptives usually 
have reduced plasma homocysteinc, high levels may be seen in 
some (56). A recent prospective study by van der Mooren er al. 
Estr,ogen-containing oral contraceptives may alter the mc- 
Honwcystinuria 
tic\mosystinuri;l is a IXC au<cjsomal I-CCCGX discnsc &r- 
acierizcd by markedly clcvatcd hornoc~s~ir.:: concentrations 
in the blood accompanied l?]< passage of homocysteinc in the 
u;inc (5s). It is 1110s; commonly caused by a deficicny of 
cystathionine be~~+ynthasc. Typical clinical manifcstatlons 
inc!ude mental retsrdaiion. skeletal at~no:malitics and lens 
disiocatio!ii. ‘T’herc is also ;I mirked tcndcncy i0 ho!h arterial 
and vc~iow t!~roir~I~c~crnholic cpisodcc. L\ ilh 2 5(l!:i ri:& hy 70 
years of ;y; (Ylhl!). T!ic frcqumy and cvtcnsivc nalurc of 
vascular disordcn in these patients has led lo cxtcnsivc work 
on the cl~idcmiolo~ic. climcal and pathophysiologic link he- 
twccn homocystcinc and vascular discasc. A rcvicw of the 
vascular pathologic and p;tlhopllysiolilgic mechanisms may 
pr(Gdci us~tiil insighls into possible mcchaiiisnis of vascular 
discasc in patients with clcvated homocysteine levels. 
Vascular pathology. Premature atherosclerosis occurs in 
patients with hrmocystinuria involving large, medium and 
small arteries and may aRect any vascular bed. There is marked 
intimal thickening as wefl a~ medial muscular fiber splitting 
an;l fraying, with an incrensc in interstitial collagen. There may 
also bc changes in the internal elastic lamina. The lesions are 
associated with prolifera:ion of pcrivascular conncrtive tissuts 
containing increased number of fihrohlasts. collagen bundles 
and small ciastic tillers (27) 
Pathophysiologic Mechanisms of 
Vascular Disease 
for the athcrogenic and thrombotic tendencies of homocystin- 
Both clinical -.,ld cxpcrimental studies suggest that ahnor- 
maliy high homocysteinc concentrations may bc responsible 
uric and hyperhomocysteinemic patients. although the exact 
mechanism has not been fully elucidated. 
Effects on endothelium. bz rig srutlicrs. Several studies 
(57j demonstrated a 10.9% decrease in fasting homocysteinc 
levels in postmenopausal women treated with continuous 
micronized 17-beta-cstradiol combined with cyclic dydrogcs- 
terone compared with baseline, prc-hormone rcplacemcnt 
levels. The decrcasc in homocystcinc levels was grcatost for 
women with high basclinc concen:rations (a 16.9% dccreasc), 
and no significant changes in homocysteine concentration 
occurred in those with low homocysteine levels. These changes 
occurred over the first 6 months of therapy, after which no 
further decrease was found. 
Penicittamine, a cysteinc analoguc with chelating properties 
used in Wilson’s disease, heavy metal poisoning, rheumatoid 
arthritis and cystinuria, may lower homoysteine levels (53), 
possibly by the formation of a tow molecular weight mixed 
have examined the direct cptotoxi!: effects of homocysteinc 
on cndothcliat cc!ts grown in tissue culture (61&Z). n.~.- 
tlomocystcine thiolactonc produced concentration-dcpcildent 
cndothctiat cctl damage that was prcvenled by calalase, sug- 
gcsting an important role for hydrogen pcroxidc in the patho- 
logic process (63). Starkebaum and Harlan ((2) found that 
copper led to the oxidation of homocysteine, producing hydro- 
gen peroxide. Cultured codotheliat celts exposed to homocys- 
teine were tysed in a time- and dose-dcpendcnt manner, hut 
only with added copper (62). These findings may he relevant to 
patlcnts with homocystinuria, in whom exceptionally high 
circulating homocysteinc and clcvated copper concentrations 
(64) may be seen. The significance in those with tcss striking 
elevations of homocystcine is unclear, especially because cop- 
//I \,i\*o stzrcfir~ Harker et al. (70) found that infusion of 
I -homoqsteine for 5 days into baboons caused patchy dcsqua- 
mat ion of vascular cr&~thcli7~m as well 3s a dccrcased platclcl 
sulvivai time. They subGgested that arterial thrombus formarion 
in homocystinuric patients resulted from sustained homcqstine- 
incluccd endothelial injury with secondary incrcasc in platelet 
consumption and atherogcnesis. To examine the long-term 
etfcct of such infusions, a J-month study was repeated in 
baboons j7i,72). Endothelial damage increased with the con- 
centration of homocysteine. In these studies, antiplatelet agents 
were administered, which prevented some of the adverse 
&cts. Conflicting results have been seen in other animal 
studies using pigs (73,74). rabbits (75.X), and monkeys 
(77,78). The reproducible findings of inducible vascular dam- 
age in the baboon (70-72), but not in other animals, suggest 
that important species-dcpendcnt rcsponscs may be involved. 
In a recent study of minipigs fed a mcthioninc-rich diet, high 
homocysteine concentrations were seen after 4 months on this 
diet, aud 2 of the t 0 animals developed thrombc~cmboli (79). 111 
addition. pathologic changes in the elastic lamina were noted 
in these animals. iioman studies using Row-mediated dilation 
have demonstrated abnormal endothelial function in homo- 
cystinuric patients but not in their heterozygotc parents (SF). 
An additional confounding issue in many studies has been 
the USC of ditTercnt Ttmls of humocystcine, especially homo- 
cysteine thiolactonc t75,76). Homocysteine thiolactone may be 
more cytotoxic ts endothelial cells than homocysteine alone, 
possibly because of an independent toxic effect of thiolactone. 
Furthermore. because the naturally occurring. form of homo- 
cysteine is the I.-isomer. usicg the unnatural D isomer (72) may 
further complicate the matter 
Effects OII platelets. In addition to :I direct pathologic cffcct 
on entlothelinl cells, n role for the effect of homocysteine on 
platelets has also been suggested. Survival of platelets has been 
shown to be impaired in baboons after administration nf 
hnmocysteine and in four patients with cystathionine beta- 
synthase deficiency (70,71). However, in other patients with 
homocystinuria, pla!elct survival has been normal (Sl,S?). 
Increased adhesiveness of platelets was first shown by 
McDonald et al. (S3), who added homocystine to normal blood 
to increase the concentration to that found in cystathionine 
beta-synthase-deficient patients. even though this was not 
found iii others (70.81,84). Different patient populations, 
- Aiinormaiitics in acicno5in e di~:tospt::lte-ind@ced plate!e! 
:igcrcfatiol: have been seen in some homocystirmric p:i:ic:nts 
hut not in others (60). Gracbcr et al. (85) showed that in vitro 
i3.i -homocysteine alters aracthdonic acid metabolism of nor- 
mai pl~:clcrs so that 12-hvdro~~-S,S,:!)-heptaclcc;ltri~~~oic acid 
and thntmboxane A, ale increased. Recently, elevated throm- 
boxanc A, formation ws reporied in homocystinuric patients 
(86). Eomocysteine-induced altera!ions in srachidonic acid 
metaboiism. resulting in the accumulation of powerful platelet 
aeorreators in patients with vascular episodes. could provide a 
p&ihle mechpoism for thromhods. 
Eftkts on clotting factors. Homoqstcinc may JISO ;~%cct 
runny f:~ctor.s involved in the clotting cascade. Gianmni ct al. 
(S7) reported reduced serum antithrom!Gn activity in seven 
homoc;istinuric patients compared with that in normai ape- 
and gender-matched control subjects. Similar findings have 
been rqortcd by others (4,88). Lcveis of antithrombin activity 
WI? of normal have been associated wit!! an increased ten- 
dency to intravascular thrombosis (89). Curiously, Palareli et 
al. (Sd) normalized the antlthrombin activity using pyridoxine 
and f&c acid, but circulating homocysteine levels remained 
high so that reduced antithrombin concentrations may not be 
related to the elevation in homocysteine (SS). A decreased 
level of Factor V (84) and reduced Factor VI1 concentrations 
have hcen seen in some studies (4.60). 
Several in vitro studies have sl:own that homocystcine 
promotes procoagulant activity (90-96). Rodgers and Kane 
(,90) found that homocystoine activated Factor V in a dosc- 
dependent manner and also increased prnthrombin activation 
of Factor XX In addition. homocysteinc inhibited protein C 
activation in cultured endothelial cells (91 j. Two studies have 
demonstrated that homoqsteine stimulates thrombomodulin 
mRNA levels in endothelial cells (92,Y3) hut may block its 
passage through the secretory pathway. resulting in the ichibi- 
tion of cell surface expression (92). Secretion of plasminngen 
activator inhibitor-I was not atrected by homocysteine (92). 
Homocysteine also inhibits the cofactor activity of cell surface 
thromhomodulin (93). Pintithrombin 111 hinding and von Wil- 
lebrand factor secretion may also be affected hy homqsteinc 
(94.95). Hajjar (96) found that homocysteine blocked the 
binding of &sue..tgpc plasminogen activator wheri added to 
human endothelinl cells. These observations suggest that ho- 
mocysteine promotes prothrombotic activities in the vascular 
endothelium. Additionally, a correlation between homocys- 
tcine and fibrinogen has been reported in a study of patients 
with coronav artev disease (97). 
Hyperhomocysteinemia and Vascular Disease 
Vascular complications in patieiits with homocystinuria 
have been well knowi: since early descriptiorls of the disease. 
However. it was not until I976 that the tirst controlled study 
showed a clear difference in methionine metabolism and 
homocysteine concentrations between patients with premature 
wlsc:li:3r &se;~sc and ~o~~KII COFII~O! subjrcts (I 1). TO date. 
iy!::n); S!UdiZS (12--!S,li.l!J--..-.,. .‘ 77 “6 :l.-19..i4.OS-i(h) invol\%lg 
hei cr:!! tl~ou:mds ol’ patients hav: 5 hown higher plasma ho- 
jij,:qst~ln~ {cvelj in PilijCntS with WSCllh diSC2SC thll in 
normal subjects. The methodologies of thcsc ditferent studies 
have varied widely not just in the technique of evaluation ana 
de6n;tic.n of by?cihonlc~y~teinenlia hut aiS0 in SiUIlp!C SkS. 
types of pati,:nLs and control subjects, c\saluation of other risk 
k~clors. slftlistica) tticbniques. types of vascular disease and 
definitions of end points. Despite their differeuces, the studies 
have similar conclusions. 
Milestone studies of homocysteine and coronary athero- 
sclerosis. Patients with coronary disease were first investi- 
gated by Wilcken and Wilcken (11). who studied mcthionine 
mstabolism in patients <St1 years old with angiographically 
proven coronary artcv discaz Using the mcthioninc loading 
test, they found higher postload homocysteinc mixed disulfide 
in patients than in control subjects. In 1983. this group 
undertook another study of patients with coronary artery 
discasc but were unable IO conlirm their previous findings (74). 
Bocrs ct al. (12) examined patients with vascular disease. 
includicg some with coronary artery disease. Using a methio- 
rime loading test, they found signifcantly higher levels of 
homocysteine i3 their patients with peripheral vascular disease 
and stroke but not in those with coronary disease. Activity of 
cystathionine beta-synthase was tow in patients with stroke and 
pcriphcral vascular disease, suggesting beterozygosity for ho- 
mocystinuria. This was not seen in the patients with coronary 
artery discasc. It should be emphasized that the numbers in 
this study were small, and most studies have since confirmed an 
association between coronary artev disc;asc and high circulat- 
ing homocysteine concentrations. Jn 1991. Clarke et al. (13) 
compared homocysteine levels after methionine loading in 
patients with premature vascular disease (65 years old) to 
t>cs!: in normal subjects. Hyperhomocysteincmia was seen in 
42% of patients with cereLovascular disease, 28% with pe- 
ripheral vascular disease and 30% with coronary artery disease 
but in none of the control subjects. After controlling for 
conventiona! risk factors, the odds ratio for vascular ciiseasc ir: 
patients with hyperhomocysteinemia was 3.3. an odds ratio 
higher than that for smoking or hypercholesterolemia. Approx- 
imately 80% of patients with high homocystcine concentra- 
tions had low cysta!hionine beta-synthase activity. Clarke et al. 
concluded that a partial deficiency of cystathioninc bcta- 
synthase was the most frequent cause of hyperhomocysteinc- 
Iuia tvcn though vitamin B,, and folatc lcvcls were lower in 
patients with high homocysteine concentrations. 
Because of the conflicting results that had been obtained in 
some of the earlier investigations and a lack of standardized 
methcdclogy, a multicenter case-control study was undertaken 
in Europe in 1990 (107). With methodology and definitions of 
vascular disease determined by consensus, -800 patients and 
800 control subjects were studied. That study confirmed the 
independent association of high homocysteine concentrations 
with all forms of premature vascular disease (105). The ‘urge 
In IN?, high hclmocysr( ~IIL’ conccn:rationa wcrc r~porfcd 
tc be at: indcpe&enr risk factor for myocardiai infarc’tion in 
mule par:icipants prospcctiveiy enrniicd in the U.S. Physicians 
Health Study (103). A threshold for increased risk of disease 
w:i.i noted a1 a homocysteinc concefitration of i5.S nmol!ml, 
corresponding to the 9Srh pcrcemile for control subjects. 
-4 similar study was reported from Norway (102). Homo- 
cysteint: concentrations were hi&r in patients who subse- 
quen!ly had a myocardial infarction than in those who did not. 
Unlike the strdy of Stampfer et al. (tO.3), however, no thrrsh- 
old phenomenon was observed. 
Mnrc recently. another study from Finland (108) found no 
rclati:)n bctwccn cormary diwasc and homocystcine in a 
group of 7423 nicn and women fotlowccl up for 9 years. Co:itrol 
subjects were selected for patients who subsequently had a 
myocardial infarction or stroke. ‘l’otal homocystcinc conccn- 
tration was measured in scrunl. Similar mean vaiucs were seen 
in patients and in control subjects (-- 10 fLmo!:liter). Because 
serum values are usually higher than those fof pidsiiia (ii;), he 
findings suggest that cxceptionaiiy tow plasma values are seen 
in this area in Finland. Although the investigators attribute this 
to a low gene frequency for cystathionine bet?-.;)athase defi- 
ciency, the technique of measurement of honc>c$s!zine may 
have accounted for the re!atively low values. Fcithcrmore. 
data were not reported for serum concentrations of B group 
vitamins in this population, which arc of major importance in 
regulating plasma homocysteine. 
In 1991. Kang ct al. (34) explored the role of the enzyme 
methylenetctrahydrofotate reductasr in patients with coronary 
artery discasz and found an abnormal thermolabile variant of 
this enzyme. In that study, but not in another (35). this 
abnormality was associated with high homocysteine concentra- 
tions. These studies have highlighted the possible importance 
of enzyme abnormalities other tbnn cystathioninc heta- 
syn!hase in the genesis of high homocysteine concentrations. 
Only recently has the reiation hctwccn homocysteine and 
concentrations of vitamin B,,, folate and vitamin B(, been 
explored in patients with coronary artery disease. Both folic 
acid and vitamin B,? were reported to be lower in patients with 
higher homocysteine ccncentrations (13,19). Negative correla- 
tions were found bchveen plasma homocysteine and both 
serum vitamin B,, and folate (41,49) in patients with coronary 
artcry disease. At the Cleveland Clinic Foundation, significant 
negative correlations both between folate and homocystcine 
and between vitamin B,, and homocysteine have been seen in 
patients with coronary artery disease as welt as in normal 
sub,jects (16,109). An additional finding of a negative corrcla- 
tion between homocysteine and vitamin B, in that study 
concurs with others (41). Frank vitamin B, deficiency was seen 
in 10% of patients compared with only 2% of normal subjects. 
Thcsc findings are consistent with earlier in vivo work in which 
arteriosclerotic lesions had developed in animals chronically 
deprived of vitamin 8, (77,78). Such studies have shifted the 
emphasis from a genetic etiology for hyperhomocysteinemia 
aad have high!ightcd the imnortanco oi ;I possibir role of low:1 
vitamin fcvcis in the tlevciopmcn: olvascular disease. including 
cforonq arlew disease. However. the precise interrelatior; 
behwen nutkma! and hereditarv factors stili requires further 
evaluation. 
H~~rhollioqsteincmia and convmtionaI risk l’uctors in 
cardiovascular disease. Scvcral s!dics ha\!< s!~own no reia- 
tion hctwce;~ plasma lmnocysteinc and serum cholest~~rol 
(14.17,22,26.100). In a recent sludy by MGlgaard et ai. (lOI), 
plasma homocysteinc correlated with both iow density lipopro- 
tein (LDL) cholesterol and apolipoprotein B levels, but these 
relations resulted from covariation with serum folate and could 
not bc confirmed with multiple linear regression analysis. King 
ct al. (IS) dcmonstratcd a correlation between plasma homo- 
cyslcinc and cholesterol in patients in whom the level of 
cho!csterol was in IIIC norm1 range, and Wu et al. (41) showed 
a correlatton with LDL cholesterol. 
Most studies have shown that smoking is not iinked with 
uomocysteinf in patients with vascular disease (14,15,22.41, 
%,100,1!)1), although a few studies have shown such a correla- 
tion (?S.110,111). No relation between blood pressure and 
homocysteine concentration has been seen in most studies of 
patients with coronary artery disease (14,35,20,22,41, 
4Y..54,Y&lOO). However. Malinow et al. (17) found that 77% of 
patients with elevated homocysteine concentraticns were hy- 
pertensive compared with 40% of those with normal Icv.%. In 
another study (38), total plasma homocysteine was signifcantly 
elevated in hypertensive patients compared with that in nor- 
motensive subjects. Homocystcine also correlated with serum 
creatininc. but. CVCII after adjusting for this, the relation 
between homocystcine and hypertension persisted. Several 
studies have showrr no correlation between diabetes or biood 
sugar and hyperhomocysteincmia (14,~7,22,41,49,99,101). 
Summary. Hyperhomocysteinemia is aa independent risk 
factor for vascular disease, including coronary atherosclerosis. 
Possible interactions with or modifications of the cllixts of 
other risk factors are suggested by some studies that have 
shown interactions with LDL fractions (41,112.113). Glueck et 
al. (110) showed thdt the risk of a myocardial infarciion in a 
group of hyperlipidemic patients was greatest in patients with 
hyperhonrocystememia and low high density lipoprotein. rais- 
ing the possibility of a clinically important interaction bctvxen 
these risk factors. 
Therapy 
Therapeutic regimens for the reduaion of homocysteine in 
patients with homocystinuria have been extensively reviewed 
risewhere (4,60). Elevaietl plasma homoqsteine levels may 
also be reduced in conditions other than homocystinuria as 
well as in normai subjects (45,114,115). Homocystelnc levels in 
folate-deficient patients can he lowered by oral folic acid 
replacement (46). In one study, the elevated homocysteinc 
concentrations in patients with renal failure decreased after 
only 2 weeks of folic acid therapy (1 IS). Maximal effects may 
be seen after 4 (116) to 6 (48) weeks of therapy. The lowest 
ctieciive dose for folic acid supplementation has not yet be-r: 
determined. Doses of 10 mg (26) or 5 mg alone (! 14) or : mg 
in conjunction with vitamins B,, and 13, may be eEecti~.e c.48). 
Recently. Ubbink ct a/. (1 :j) demonstrated the elEsacy of a 
dose as low as 0.6j mg folic acid, which lowered plasma 
homocystcine concentrations in patients with high levels by 
42%. BrattstrEm et al. (11’7) noted significantly lower homo- 
cysteinc concentrations in middle-aged and elderly subjects 
taking multivitamins containing doses of folic acid ranging 
from only 200 to 400 pg. Homocysteine values increase if 
vitamin therapy is discontinued (1.16). In one study, homocys- 
teinc concentrations returned to pretreatment levels vrithin 10 
weeks of cessation of folic acid therapy in renal transplant 
recipients (i 16). 
Because vitamin B,? is a cofactor in remethylation and no: 
a cosubstrate, B,, therapy wou!d not be expected to reduce 
homocysteine unless there is suboptimal B12 status or frank 
B,z deficiency. Resul!s of a limited number of studies support 
!hcse expectations (114). Administration of vitamin B, alone in 
normal subjects does not lower fasting plasma homcrysteine 
concentration (I Id,! IS). 
Therapeutic studies in patients with v3scul;?t disease. 
Several studies have been performed in patients with periph- 
eral and cerebrovascular disease. In one study, folic acid 
combined with vitamin B, reduced fasting homocysteine levels 
by 53% (26). However, vitamin B,, when administered alone, 
had no effect on f a&s homocysteine concentrations but may 
lower the levels after a methioninc load (26). Similar ohserva- 
tions have been made by others (12,104,llS). 
Thehcsc findings have prompted studies of folic acid and 
vitamins B,, and B,, ,n patients with coronary athcrosclcrosis 
to redilce homocysteine concentrations (104,11Y-131). I Ind- 
gtcn et al. (121) have leceutly s~scessfully used doses of 2.5 and 
10 mg of folic acid to reduce homocysteine concentrations in a 
small group of patients after myocardial infarction. Dudman et 
al. (104) lowered homocysteine concentrations in patients with 
coronary disease using a variety of treatment regimens, includ- 
ing folic acid, vitamin B,, choline and betaine. Ryan et al. 
(IlY), using a combination of vitamin B, and folic acid, 
obsencd a decrease in postload plasma lzmocystcine concen- 
tration by 1.5%. In a recent study, Saltxman et al. (120) used 
placebo, folic acid. vitamins B Iz and B, together, or a combi- 
nation of all three vitamins in patients undergoing coronary 
angioplasty (120). Folic acid a!one, or combined with vitamins 
B,, and B,, or the combination of B,, and B, aione. each 
reduced homocysteine concentrations. Recentiy, Naurath et al. 
(122) used an intramuscular regimen of I.1 mg of folate, 1 mg 
of vitamin B,> and 5 mg of B, in a wide variety of patients? 
including those with ~xxular disease, and reduced 8% of 
elevated homorysteine levels to the normal range. In prclimi- 
nary s!udi?s at the Cleveland Clinic, 400 pg of folic acid 
cG,.,bincd with vitamins B!, and $ reduced plasma homocys- 
teinc concentrations by 15% in patients with coronary disease. 
However, -35% of patients showed no significant response. 
The relatively smal! change in homocysteine concentration 
produced by this treatment regimen and ihe reiativzly large 
pe!x:ntage of IlcxlresponLicrs S& . “OCSl 1113! a dose c400 pg of Cardiac transplantetion. Coronary c,therort.lerosis is a ma- 
foiate should bs used. The optimal dose and vitamiil combi- jor cause of !ate morbidity and mortality in cardiac transplant 
nation to produce the maximal rzduction of homocysteine in recipients. After transplantation, homocysteine concentra- 
coronary artery disease has not yc~ been established. nor has iians have been found to incrcasc (126,127). Rerger et al. (127) 
the effect of lowering homocysleine concentration on cardio- recently reported a study of 41 recipients in whom homocis- 
vascular risk. teine levels increased 70% after heart transplantation, whereas 
B,, and folate levels decreased by 49% and 203b, respectively. 
Glomeralar filtration rate also decreased 25% (127). Levels in 
Enrxging Aspects of Homwysttiine and 
Coronary Disease 
Effect: of getlder, age and race. Although high circulating 
hol’locysteine concentrations are associated with coronary 
artery disease, most previous studies have focused on younger 
male patient populations. However, in an earlier study, Kang 
et al. (15) pointed to elevated homocystcine concentrations in 
women with coronary disease, although their precise risk of 
disease with hyperhomocysteincmia remained unclear. At this 
institution. an odds ratio for coronary artery disease in women 
of 3.5 (109) was founli, showing thnt there is an increased risk 
of coronary disease ir women as well as in men. We have also 
noted odd: ratios for :oronaty disease of 3.2 in bo:h male and 
female patients >6.5 !‘enrs old compared with 2.9 <65 years 
old, suggesting that high homocysteinc concentrations may 
also be an important risk factor in the elderly (109). Recently, 
MLMartin et al. (123) examined the effect of race and gender 
on homocysteine concentrations in patients with vascular 
disease. They found !hat white men had the highest levels (14.0 
pmol/liter), which were significantly higher than those in wL:e 
women (8.5 ~mol/liter) or black men (IV.0 pmoliliter). There 
was no significant difference between black men and women 
(10.0 bmoliliter vs. 10.4 pmol!liter). These preliminary data 
suggest a possible difference in the prevalence and impact of 
hyperhomocystenemia on vascular disease between races, 
though this study included only a small number of patients. 
Additionally. ages and vitamin levels were not reported. Fur- 
ther studies are needed to elucidate the impact of race on 
homocysteine levels and its relative risk. 
transplant recipients studied at rot + *I ‘\ Cleveland Clinic Founda- 
tion were 18.5 pmol/liter but were only 11.0 pmoliliter in age- 
a;ld gender-matched control subjects. Deficiencies of both 
folate and vitamin B, (pyridcxal 5’-phosphate ~20 pmol/liter) 
were more common in thl: transplant group, demonstrating the 
presence of widespread nutrient disorders in these patients. 
However, renal function was also impaired, possibly from 
toxicity of the immunosuppressive agents. Mechanisms of 
these alterations in homocysteine metabolism require further 
evaluation, but the abnormalities of B,,. folate and renal 
function suggest a complex ancl probably multifactorial ctiol- 
W. 
Severity of coronary artery disease. Increasing severity of 
carotid disease with increasing homocysteine le?;els has been 
seen (106,124), but reports on the relation between severity of 
coronary disease and homocystcinc concentration are conflict- 
ing. Kang et al. (15) reported no correlation behveen homo- 
cysteine concentrations and Gensini scores of severity of 
coronary disease. However, Uhbink et al. (21) did show a 
correlation between homocysteine levels and the number of 
occluded coronary arteries, consistent with the findings of 
others (97). Using intravascular ultrasound, we observed less 
intracoronary plaque in “normal” reference segments in pa- 
tients undergoing coronary interventions with plasma homo- 
cysteine <:I pmol/liter compared with those with hi&r 
concentrations (125). In addition, the patients with lower 
homocysteine concentrations had fewer adverse clinical out- 
comes after coronary intervention. The precise relation be- 
tween homocysteine and the severity and distribution of coro- 
nary disease requires further study. 
Conclusions 
Prospective and case-coi..:ol studies have shown that mod- 
estly elevated plasma homocysteine concentration is a risk 
factor for coronary artery disease. Elevations in Lmocysteinc 
may be caused by a combination of nutritional and genetic 
factors. The exact mechanism for the development of athero- 
sclerosis in this setting is unclear. Folic acid may be used to 
reduce homocysteine concentration in patients with coronary 
artel); disease, eiihcr aione or combined with other R vitamins. 
The optimal doses and combinations of these substances 
remain unclear and are currently under investigation. The 
possible beneficial effect of such treatment on coronary risk, 
including effects on cardiac aorbidity and mortality, will 
require a long-term, prospective randomized piacebo- 
controlled trial. 
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